British Journal of Pharmacology · 10 Nov 2026
Interpretable multimodal network analysis of lipid‐lowering therapies
Daniele Dall'Olioh-index 10, Matteo Pedrelli, Claudia Sala, Francesca Grassi, Ruisheng Wang, Osman Ahmed, Carsten O. Daub, Daniel Remondini, Gastone Castellani, Davide Gentilini, Chiara Pirazzini, Paolo Garagnani, Enrico Petrillo, Matteo Bersanelli, Elliott M. Antman, Joseph Loscalzo, Paolo Parinih-index 50
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Background and Purpose Multimodal integration of clinical and omics data could clarify the hepatic mechanisms of lipid‐lowering therapies, but interpretable methods for heterogeneous data remain limited. The objective was to apply interpretable multimodal networks (IMNs), a topology‐aware framework that condenses heterogeneous omics and clinical data into compact, cross‐modal modules, to characterize treatment‐specific hepatic responses to simvastatin and ezetimibe. Experimental Approach In the Stockholm Study, patients scheduled for cholecystectomy were randomized for 4 weeks to simvastatin, ezetimibe, their combination or placebo. We integrated liver transcriptomics and DNA methylation with plasma/bile biochemistry, including lipoprotein functionality, on the human protein–protein interactome to build treatment‐specific IMNs and evaluated selected network‐derived predictions in a human hepatocyte‐like model (SOAT2‐only‐HepG2). Key Results IMNs reduced dimensionality while preserving network topology, producing distinct molecular signatures for simvastatin, ezetimibe and combination therapy that mapped to different biological processes; the placebo network was less multimodal and more fragmented. IMNs highlighted apolipoprotein‐centred modules and predicted drug effects on APOA2, PPARA and PTPRS, linked to plasma C‐peptide. In SOAT2‐only‐HepG2 cells, selected predictions were supported experimentally, including APOA2 induction and ezetimibe‐associated PTPRS upregulation. Conclusions and Implications IMNs provide a practical, interactome‐based route from multimodal patient data to focused, testable hypotheses about lipid‐lowering therapies, yielding compact features suitable for downstream predictive modelling while retaining biological interpretability.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Paolo Parini has the highest h-index among the authors (50).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (59)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 39 more references
A free account opens the rest of the citing papers and references on every paper’s page.